Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 15, 2006 (Vol. 26, No. 8)


  • Interesting products
  • Weak in content
The latest reported occurrence of mad cow disease in the U.S. recently hit the newswires. Why do I mention that here? Well, to be honest it is a bit out of place, but the issue of animal health is, after all, what Immucell is all about. Describing itself as a “product-driven company with a focus on solving problems for the dairy and beef industries worldwide,“ Immucell provides products for the prevention, diagnosis, and treatment of diseases relevant to the dairy and beef industries. Apparently focused on the antibacterial agent Nisin, Immucell provides products for common cattle diseases, including mastitis and calf scours, as well as prevention approaches and diagnostics for other diseases. According to the Website, they now have an alliance with Pfizer, so expect to hear big things from Immucell in the future.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »